Worse Prognosis in Papillary, Compared to Tubular, Early Gastric Carcinoma

Huiping Yu(Nanjing Drum Tower Hospital), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Jiong Shi(Nanjing Drum Tower Hospital), Xiaoping Zou(VA Boston Healthcare System), Fang Cheng(Nanjing Drum Tower Hospital), Lin Chen(Chinese PLA General Hospital), Xianshan Fan(Veterans of Foreign Wars)
Journal of Cancer
December 29, 2016
10.7150/jca.17326
Cited by 37

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
|Journal of Biological Chemistry|1993|375
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362